Real incidence and management of patients with suspected iodinated contrast media allergy in our area.

IF 2.1 4区医学 Q3 ALLERGY

Allergologia et immunopathologia Pub Date : 2025-09-01 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i5.1352

M Jesús Trujillo Trujillo, Victoria Villalobos-Violán, Arturo Toledo Gutiérrez, Mar Gandolfo-Cano, Ester Mohedano Vicente, Eloína González-Mancebo

{"title":"Real incidence and management of patients with suspected iodinated contrast media allergy in our area.","authors":"M Jesús Trujillo Trujillo, Victoria Villalobos-Violán, Arturo Toledo Gutiérrez, Mar Gandolfo-Cano, Ester Mohedano Vicente, Eloína González-Mancebo","doi":"10.15586/aei.v53i5.1352","DOIUrl":null,"url":null,"abstract":"Introduction: Adverse reactions to iodinated contrast media (ICM) are very common due to its widespread use. Despite the fact that overall incidence of hypersensitivity reactions (HSRs) to ICM is low, the risk of severe outcomes needs a careful patient evaluation and management.Methods: We conducted a retrospective epidemiological study that included patients referred to our Allergy Unit for suspected allergy to ICM in whom we carried out a protocolized allergic study based on skin and drug provocation tests (DPT).Results: A total of 108 patients were tested and allergy to ICM was confirmed in 29 (26.9%) and assumed in 9 (8.3%). All these patients tolerated DPT with alternative ICM. The most frequently involved contrasts in confirmed HSR were iodixanol and iohexol, and iopromida was the best tolerated. Out of a total of 125 DPT, we obtained 26 positive results with only two systemic reactions (mild).Conclusion: In most of the patients in our sample, allergy to ICM was ruled out, and in allergic patients, tolerance to an alternative ICM was established. Our protocol is safe and allows patients to receive ICM in the future.","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 5","pages":"1-4"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i5.1352","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Adverse reactions to iodinated contrast media (ICM) are very common due to its widespread use. Despite the fact that overall incidence of hypersensitivity reactions (HSRs) to ICM is low, the risk of severe outcomes needs a careful patient evaluation and management.

Methods: We conducted a retrospective epidemiological study that included patients referred to our Allergy Unit for suspected allergy to ICM in whom we carried out a protocolized allergic study based on skin and drug provocation tests (DPT).

Results: A total of 108 patients were tested and allergy to ICM was confirmed in 29 (26.9%) and assumed in 9 (8.3%). All these patients tolerated DPT with alternative ICM. The most frequently involved contrasts in confirmed HSR were iodixanol and iohexol, and iopromida was the best tolerated. Out of a total of 125 DPT, we obtained 26 positive results with only two systemic reactions (mild).

Conclusion: In most of the patients in our sample, allergy to ICM was ruled out, and in allergic patients, tolerance to an alternative ICM was established. Our protocol is safe and allows patients to receive ICM in the future.

查看原文本刊更多论文

本地区疑似碘造影剂过敏患者的真实发病率及处理。

由于碘造影剂（ICM）的广泛使用，其不良反应是非常常见的。尽管ICM超敏反应（HSRs）的总体发生率很低，但严重后果的风险需要仔细的患者评估和管理。方法：我们进行了一项回顾性流行病学研究，纳入了因疑似对ICM过敏而转诊到我们过敏科的患者，我们对这些患者进行了基于皮肤和药物激发试验（DPT）的过敏研究。结果：108例患者中，29例（26.9%）确诊为ICM过敏，9例（8.3%）推定为ICM过敏。所有这些患者耐受DPT和替代ICM。在确诊的HSR中，最常涉及的对照物是碘沙醇和碘己醇，而碘丙咪达的耐受性最好。在125例DPT中，我们获得了26例阳性结果，只有2例全身反应（轻度）。结论：在我们的样本中，大多数患者排除了对ICM的过敏，在过敏患者中，对替代ICM的耐受性建立。我们的方案是安全的，并允许患者在未来接受ICM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergologia et immunopathologia 医学-过敏

CiteScore

3.70

自引率

0.00%

发文量

131

审稿时长

6-12 weeks

期刊介绍： Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.